# PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

> **NCT05229315** · PHASE2 · UNKNOWN · sponsor: **XIANG YANQUN** · enrollment: 45 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma
- T2-3N0 or T1-2N1
- EBV-DNA≤4000 Copy/ml

## Interventions

- **DRUG:** Toripalimab
- **PROCEDURE:** Intensity modulated radiotherapy

## Key facts

- **NCT ID:** NCT05229315
- **Lead sponsor:** XIANG YANQUN
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-12
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05229315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05229315, "PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05229315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*